HIF1A and cancer: In summary, our findings indicate that 1, 9 PA can sensitize cancer cells to cetuximab-mediated anti-EGFR therapy by downregulating HIF-1α and can enhance cellular response to cetuximab treatment in cancer cells bearing oncogenic Ras mutations.